Trikafta® modulator therapy and glycemic status in pediatric patients with cystic fibrosis Public Deposited

The development of cystic fibrosis-related diabetes may negatively affect lung health, nutrition and growth status, and mental health of individuals with cystic fibrosis. In this retrospective medical record review study, we will assess changes in glycemic status before and after initiating Trikafta® modulator therapy by utilizing biochemical indicators of glucose homeostasis (hemoglobin A1C, oral glucose tolerance test (OGTT), fasting glucose). We will also assess changes in body mass index (BMI) and lung function (pFEV1) in relation to initiation of Trikafta®. Following analysis of changes within categories, we will then investigate associations between lung function, anthropometrics, and glycemic status to understand the interrelationships between these components of health. The overall goal of this study is to assess the long-term effects of Trikafta® on glycemic status in pediatric patients (ages 11-21 years) with cystic fibrosis.

Publication Date
  • 2022
Document type